Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bluejay DiagnosticsBJDX -7.46%22 EV-to-EBIT is 0.39 as of Aug. 02, 2026, which is 37% below its 10-year median of 0.62. GuruFocus rates BJDX with a GF Score™ of 22/100. Among 470 Medical Devices & Instruments companies, Bluejay Diagnostics ranks better than 98.09% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Bluejay Diagnostics's Enterprise Value for the quarter that ended in Mar. 2026 was $-1.68 Mil.
Bluejay Diagnostics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.92 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bluejay Diagnostics EV-to-EBIT Related Terms
Bluejay Diagnostics EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Bluejay Diagnostics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Bluejay Diagnostics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bluejay Diagnostics EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bluejay Diagnostics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Bluejay Diagnostics's EV-to-EBIT falls into.
Bluejay Diagnostics's current Enterprise Value is $-2.68 Mil.
Bluejay Diagnostics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.92 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bluejay Diagnostics (BJDX) has a EV-to-EBIT of 0.39 as of Aug. 02, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Bluejay Diagnostics and its competitors. This is 37% below median its historical median of 0.62. According to the industry distribution chart, Bluejay Diagnostics ranks #9 out of 470 companies in the Medical Devices & Instruments industry, placing it in the top 1.9%.
Is Bluejay Diagnostics' EV-to-EBIT too high?
Bluejay Diagnostics' current EV-to-EBIT of 0.39 is 37% below median its 10-year median of 0.62. The Medical Devices & Instruments industry median EV-to-EBIT is 18.85. Bluejay Diagnostics' value of 0.39 is 97.9% below this industry median. Based on the distribution chart, Bluejay Diagnostics ranks #9 out of 470 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Bluejay Diagnostics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Bluejay Diagnostics' EV-to-EBIT compare to VTAK and PFSA?
According to the Medical Devices & Instruments industry distribution chart, Bluejay Diagnostics ranks #9 out of 470 companies for EV-to-EBIT. This places Bluejay Diagnostics in the top 2% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 18.85. Bluejay Diagnostics' value of 0.39 is 97.9% below this benchmark. While the company's 10-year median is 0.62 vs. the industry median of 18.85, Bluejay Diagnostics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.85, based on 470 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bluejay Diagnostics's current EV-to-EBIT of 0.39 is 97.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Bluejay Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bluejay Diagnostics's current EV-to-EBIT is 0.39, which is 37% below median its own 10-year median of 0.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bluejay Diagnostics stock overvalued right now?
Bluejay Diagnostics (BJDX) has a current EV-to-EBIT of 0.39. The current EV-to-EBIT is 0.39, which is 37% below median its 10-year median of 0.62 and 97.9% below the Medical Devices & Instruments industry median of 18.85. Bluejay Diagnostics' overall GF Score™ is 22/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Bluejay Diagnostics (BJDX), the current EV-to-EBIT is 0.39 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bluejay Diagnostics Inc is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay's first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and quicker triage/treatment decisions.
22GF Score
Get the complete analysis for BJDX
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJDX has been successfully added to your 
